Bulltick Wealth Management LLC Acquires New Position in Johnson & Johnson $JNJ

Bulltick Wealth Management LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,235 shares of the company’s stock, valued at approximately $341,000.

Several other large investors have also added to or reduced their stakes in the company. GFG Capital LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter valued at $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson during the first quarter worth about $48,000. Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the 1st quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $65,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $196.00 on Monday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $197.18. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm’s fifty day moving average is $185.81 and its 200 day moving average is $170.14. The company has a market cap of $472.22 billion, a price-to-earnings ratio of 18.92, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on JNJ. Citigroup lifted their price objective on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, October 15th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Finally, Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.